Navigation Links
Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest

BOSTON--(BUSINESS WIRE)--Apr 26, 2007 - A new study published today in the New England Journal of Medicine ("A National Survey of Physician-Industry Relationships") on the extent of doctor and pharmaceutical company relationships, highlights the need for profession-wide and public policy reforms promoted by The Prescription Project. The article concludes that the existing, voluntary PhRMA (Pharmaceutical Research and Manufacturers of America) Code isn't working.

The Prescription Project offers solutions to this continuing crisis by outlining specific suggestions for academic medical centers, physician leadership and policy makers to end industry influence on medicine:

"The fact that 94% of physicians have relationships with pharmaceutical companies is a clear barrier to a trusting and effective doctor patient relationship. Academic medical centers and professional medical societies must take the lead in protecting public trust in the medical profession by adopting reforms," said David J. Rothman, PhD, Associate Director of The Prescription Project and president of Institute on Medicine as a Profession, which funded the NEJM study.

"Though the financial ties are extensive, the change we are advocating for can be made and must be made. One can look to the example of several leading academic medical centers to see that this approach can work. We now need a profession-wide adoption of those policies at all hospitals, physician practices and professional medical societies," Rothman continued.

"Legislators across the country are concerned about the influence of the pharmaceutical industry on doctors, and how it affects patient care and costs," said Rob Restuccia, Director of The Prescription Project. "Proposals to stem the tide of industry gifts and end data-mining are moving to the floors of state houses nationwide."

-- Today, New York legislators joined with national consumer and senior groups to introduce a pair of bills to end data-mining and restrict industry gifts.

-- Earlier this week, Minnesota state officials announced a joint effort with consumers and health groups there to strengthen the state's first-in-nation 1993 gift law.

-- Maine and Vermont legislators are debating gifts disclosure and data-mining bills now, and a hearing on an academic-detailing bill is scheduled in Maine next Monday.

"Our ability to support and strengthen coalitions in states like these is crucial to getting policies that preserve the doctor-patient trust in place," Restuccia said.

For more information, visit .


for The Prescription Project
Diana Pisciotta, 617-784-5256
Terence Burke, 617-482-0042


Related medicine technology :

1. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
2. Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
3. Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
4. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
5. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
6. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
7. MUSC Research Offers Hope for Those Resistant to Depression Treatment
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Antibiotics Dont Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):